Maraviroc shows promise in HIV-infected children
Maraviroc plus optimized background therapy in HIV-infected children appeared well tolerated and effective, according to study results presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
“Maraviroc is a CCR5 antagonist, approved to treat adults infected with CCR5-tropic HIV-1, but not yet approved for pediatric use,” researchers wrote.
The multicenter study included 78 treatment-experienced HIV-infected children to evaluate safety, tolerability and pharmacokinetics of maraviroc (Selzentry, ViiV Healthcare) plus optimized background therapy. Dose adjustments occurred at week 2 if average concentrations were less than 100 ng/mL. Maintenance maraviroc doses ranged from 50 mg to 450 mg twice daily.
Researchers did not report any deaths or discontinuations due to adverse events. Seventeen percent of participants had 17 treatment-emergent, non-treatment-related serious adverse events, including infections and infestations; gastrointestinal disorders; hepatobiliary disorders; investigations; musculoskeletal and connective tissue disorders; psychiatric disorders; and skin and subcutaneous tissue disorders.
Eighteen percent of participants experienced treatment-related adverse events, including gastrointestinal disorders; nervous system disorders; hepatobiliary disorders; metabolism and nutrition disorders; skin and subcutaneous tissue disorders; reproductive system and breast disorders; psychiatric disorders; and cardiac disorders.
For more information:
Giaquinto C. Abstract MOAB0103. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.